Shire receives first Vyvanse patent challenge, from Sandoz
This article was originally published in Scrip
Executive Summary
Sandoz, Novartis' generics arm, has filed an ANDA with the US FDA for a generic version of the Shire Pharmaceutical's top-selling drug for attention deficit hyperactivity disorder (ADHD) product, Vyvanse (lisdexamfetamine dimesylate), challenging Shire's patents.